| Scl represses cardiomyogenesis in prospective hemogenic endothelium and endocardium B Van Handel, A Montel-Hagen, R Sasidharan, H Nakano, R Ferrari, ... Cell 150 (3), 590-605, 2012 | 182 | 2012 |
| Enhanced safety and efficacy of protease-regulated CAR-T cell receptors L Labanieh, RG Majzner, D Klysz, E Sotillo, CJ Fisher, JG Vilches-Moure, ... Cell 185 (10), 1745-1763. e22, 2022 | 145 | 2022 |
| Cell-binding assays for determining the affinity of protein–protein interactions: technologies and considerations SA Hunter, JR Cochran Methods in enzymology 580, 21-44, 2016 | 84 | 2016 |
| An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA N Mehta, S Maddineni, RL Kelly, RB Lee, SA Hunter, JL Silberstein, ... Scientific reports 10 (1), 15171, 2020 | 48 | 2020 |
| An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy SA Hunter, BJ McIntosh, Y Shi, RAP Sperberg, C Funatogawa, ... Communications Biology 4 (1), 452, 2021 | 27 | 2021 |
| Development of a protease biosensor based on a dimerization-dependent red fluorescent protein AC Mitchell, SC Alford, SA Hunter, D Kannan, RA Parra Sperberg, ... ACS chemical biology 13 (1), 66-72, 2018 | 24 | 2018 |
| Engineered CD47 protects T cells for enhanced antitumour immunity SA Yamada-Hunter, J Theruvath, BJ McIntosh, KA Freitas, F Lin, ... Nature, 1-9, 2024 | 20 | 2024 |
| Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein AC Mitchell, D Kannan, SA Hunter, RAP Sperberg, CH Chang, ... Journal of Biological Chemistry 293 (14), 4969-4980, 2018 | 10 | 2018 |
| Stem cell factor lifted as a promising clinical target for cancer therapy Y Shi, S Hunter, T Hunter Molecular cancer therapeutics 18 (8), 1337-1340, 2019 | 7 | 2019 |
| Directed evolution of genetically encoded LYTACs for cell-mediated delivery JL Yang, SA Yamada-Hunter, L Labanieh, E Sotillo, JS Cheah, ... Proceedings of the National Academy of Sciences 121 (13), e2320053121, 2024 | 4 | 2024 |
| An engineered NKp46 antibody for construction of multi-specific NK cell engagers RB Lee, S Maddineni, M Landry, C Diaz, A Tashfeen, SA Yamada-Hunter, ... Protein Engineering, Design and Selection 37, gzae013, 2024 | 1 | 2024 |
| Abstract B052: IKAROS mediates antigen escape following CD19-or CD22-targeted immunotherapies in r/r B-ALL P Domizi, J Sarno, A Jager, M Merchant, K Pacheco, S Yamada-Hunter, ... Cancer Research 84 (17_Supplement), B052-B052, 2024 | | 2024 |
| Soluble leukemia inhibitory factor receptor polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity S Yamada-Hunter, JR Cochran US Patent 12,049,490, 2024 | | 2024 |
| IKAROS facilitates antigen escape in the face of CD19-and CD22-targeted therapies for B-cell acute lymphoblastic leukemia P Domizi, J Sarno, A Jager, M Merchant, KZB Pacheco, ... bioRxiv, 2024.11. 01.621347, 2024 | | 2024 |
| An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma BJ McIntosh, GG Hartmann, SA Yamada‐Hunter, P Liu, CF Williams, ... Bioengineering & Translational Medicine 8 (6), e10573, 2023 | | 2023 |
| Harnessing macrophages, while protecting T cells, enhances anti-tumor efficacy SA Yamada-Hunter, J Theruvath, MT Radosevich, BJ McIntosh, ... Cancer Research 83 (7_Supplement), 5741-5741, 2023 | | 2023 |
